Redcare Pharmacy: A Market Misstep Creates a Potential Opportunity

Redcare Pharmacy NL0012044747

A sharp sell-off in shares of Redcare Pharmacy on Tuesday appeared more connected to sector-wide sentiment than the company's own fundamentals. The trigger was disappointing preliminary 2025 figures and a weak fourth-quarter update from its Swiss competitor, DocMorris, which spooked investors across the online pharmacy space.

DocMorris reported that its growth in electronic prescriptions (E-Rx) was falling short of expectations. This news prompted a dramatic plunge in its own stock, which traded between 6.13 and 6.50 CHF in January following the announcement. The market's reaction was broad and undiscriminating: investors sold shares of Redcare in tandem, pushing the stock perilously close to its 52-week low of approximately €59.45. This occurred despite Redcare's operational performance being widely viewed as significantly stronger.

Divergent Fundamentals and Analyst Conviction

The contrasting health of the two businesses was highlighted by Barclays analyst Sarah Roberts on January 20. She reaffirmed her "Overweight" rating on Redcare, emphasizing its superior scale effects and more robust balance sheet. Roberts argued that while DocMorris struggles in the prescription segment, Redcare is better positioned to navigate current market turbulence.

Key financial projections underscore this divergence:
* DocMorris anticipates 2025 revenue growth of 11.1%, reaching 1.19 billion CHF.
* Redcare is forecast to achieve roughly 24% revenue growth in 2025, with sales projected at 2.9 billion EUR.

Further concerns linger over DocMorris's liquidity, with Zürcher Kantonalbank recently noting worries about its funding requirements through the end of 2027. Redcare faces no comparable financial uncertainties—a stability advantage the market temporarily overlooked.

Insider Confidence and Growth Prospects

A vote of confidence comes from company insiders, who hold approximately 13.5% of Redcare's shares. With a market capitalization of around 1.31 billion euros as of mid-January 2026, growth-oriented analysts consider the valuation attractive. This view is supported by consensus estimates pointing to annual profit growth exceeding 60%.

The immediate focus for investors is whether Redcare's upcoming detailed financial results can demonstrate that its prescription business remains decoupled from the issues facing its Swiss rival. Technically, the €60 support level is critical; a sustained break below it could trigger further selling pressure. If the share price holds above this level, the positive assessment from analysts like those at Barclays is likely to regain influence.

@ boerse-global.de | NL0012044747 REDCARE